(R01 Clinical Trial Not Allowed)
Funding Opportunity Announcement (FOA) Numbers:
PA-19-081
(R21 Clinical Trial Not Allowed)
Funding Opportunity Purpose
The purpose of this Funding Opportunity Announcement is to support the development of rapid, sensitive, specific, simple, and cost-effective diagnostics for primary health-care settings (hospitals and point-of-care).
Specific areas of research interest
This FOA will support diagnostics research activities, including efforts to: 1) identify biomarkers of invasive fungal disease and/or determine antifungal susceptibility, 2) develop an assay to reliably demonstrate the presence or absence of novel biomarkers or determine drug sensitivities, 3) explore and assess strategies for optimizing sample type and/or sample volume, and develop or improve concentration or enrichment methods to support overall assay development in any novel diagnostic schema, 4) apply technological/methodological advancement strategies in both target identification and assay development, which may include approaches designed to substantially improve existing methods. Diagnostic approaches that detect one or more fungal pathogens and provide results more rapidly than current culture-dependent methods are strongly encouraged.
It is possible that a single target either from the pathogen or induced via the host’s response will be insufficient to provide the required sensitivity and specific early diagnostic capabilities. Identification of multiple targets and development of a multiplex assay(s) may be required to distinguish between a fungal pathogen only colonizing a host verses causing active disease, as well as identifying the infectious agent.
Eligibility
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Foreign (non-U.S.) institutions must follow policies described in the NIH Grants Policy Statement, and procedures for foreign institutions.
Award Budget
PA-19-080
Application budgets are not limited but need to reflect the actual needs of the proposed project.
PA-19-081
Direct costs are limited to $275,000 over a two-year project period, with no more than $200,000 in direct costs allowed in any single year
Award Project Period
PA-19-080
The maximum project period is 5 years.
PA-19-081
The maximum project period is two years.
Key Dates
PA-19-080
Open Date (Earliest Submission Date): January 05, 2019
PA-19-081
Open Date (Earliest Submission Date):January 16, 2019
Letter of Intent Due Date(s): N/A
*Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Expiration Date: January 8, 2022
Deadline
Application Due Date(s)
PA-19-080
The first standard application due date for this FOA is February 05, 2019.
Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
PA-19-081
The first standard application due date for this FOA is February 16, 2019.
Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
